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The pathogenesis of diabetic nephropathy is associated
with abnormalities of renal nitric oxide generation and
signaling. We evaluated the effect of BI 684067, a solu-
ble guanylate cyclase (sGC) activator, in combination
with the current standard of care (SoC), on the progres-
sion of diabetic nephropathy. Male ZSF1 rats were
administered enalapril (3 mg/kg in drinking water) for
10 days, after which they were randomized to either
continue to receive enalapril alone or the combination
of enalapril and one of three doses of BI 684067 (20, 40
and 80 mg/kg) in chow for 10 weeks. Weekly urinary
protein to creatinine ratio (UPCR) as well as daily mean
arterial pressure (MAP) and heart rate (HR) were mea-
sured. At study end, kidneys were assessed for glomerular
lesions and a-SMA expression, a marker of myofibroblast
activation. The combination of BI 684067 and enalapril
resulted in significant dose-dependent decreases of the
following when compared to enalapril alone: UPCR (BI
684067 at 20, 40, and 80 mg/kg : 27, 39, 48% reductions
respectively), incidence of glomerulosclerosis (BI 684067
at 20, 40, and 80 mg/kg: 29, 32, 44% reductions, respec-
tively) and a-SMA expression (BI 684067at 20, 40, and
80 mg/kg : 26, 40, 42% reductions, respectively). The
MAP was significantly reduced by BI 684067 in combina-
tion with enalapril (-3 mm Hg vs enalapril alone at the
doses of 40 and 80 mg/kg), however there was no signifi-
cant effect on HR. These results support the efficacy of
an sGC activator in preventing the progression of
diabetic nephropathy when combined with the SoC.
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